Identification of Novel pro-α2(IX) Collagen Gene Mutations in Two Families with Distinctive Oligo-Epiphyseal Forms of Multiple Epiphyseal Dysplasia  by Holden, Paul et al.
Am. J. Hum. Genet. 65:31–38, 1999
31
Identification of Novel pro-a2(IX) Collagen Gene Mutations in Two
Families with Distinctive Oligo-Epiphyseal Forms of Multiple Epiphyseal
Dysplasia
Paul Holden,1 Elizabeth G. Canty,1 Geert R. Mortier,2 Bernhard Zabel,3 Jurgen Spranger,3
Andrew Carr,4 Michael E. Grant,1 John A. Loughlin,5 and Michael D. Briggs1
1Wellcome Trust Centre for Cell-Matrix Research, School of Biological Sciences, University of Manchester, Manchester, England; 2Department
of Medical Genetics, University Hospital of Ghent, Ghent, Belgium; 3Childrens Hospital, University of Mainz, Mainz, Germany; and 4Nuffield
Orthopaedic Centre and 5Cellular Genetics Group, Institute of Molecular Medicine, John Radcliffe Hospital, Oxford
Summary
Multiple epiphyseal dysplasia (MED) is a genetically het-
erogeneous disorder with marked clinical and radio-
graphic variability. Traditionally, the mild “Ribbing”
and severe “Fairbank” types have been used to define a
broad phenotypic spectrum. Mutations in the gene en-
coding cartilage oligomeric-matrix protein have been
shown to result in several types of MED, whereas mu-
tations in the gene encoding the a2 chain of type IX
collagen (COL9A2) have so far been found only in two
families with the Fairbank type of MED. Type IX
collagen is a heterotrimer of pro-a chains derived
from three distinct genes—COL9A1, COL9A2, and
COL9A3. In this article, we describe two families with
distinctive oligo-epiphyseal forms of MED, which are
heterozygous for different mutations in the COL9A2
exon 3/intron 3 splice-donor site. Both of these muta-
tions result in the skipping of exon 3 from COL9A2
mRNA, but the position of the mutation in the splice-
donor site determines the stability of the mRNA pro-
duced from the mutant COL9A2 allele.
Introduction
Multiple epiphyseal dysplasia (MED; MIM 226900) is
a relatively common osteochondrodysplasia resulting in
mild short stature and early-onset osteoarthritis (Inter-
national Working Group on Constitutional Diseases of
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Bone 1998). MED is clinically and radiographically het-
erogeneous, and, typically, the mild “Ribbing” (Ribbing
1937) and severe “Fairbank” (Fairbank 1947) types are
used to define a broad phenotypic spectrum that also
includes a number of unclassified types of MED. Indi-
viduals with MED are usually diagnosed in mid to late
childhood, because of pain and stiffness of the large
joints, such as ankles, knees, or hips (Rimoin and Lach-
man 1993). In some types of MED, severe progressive
osteoarthritis results in hip replacement as early as the
3d or 4th decade of life.
Sir Thomas Fairbank published, 150 years ago, the
first detailed account of a disorder that he described as
“dysplasia epiphysialis multiplex” (Fairbank 1947).
This remarkable paper was the product of 135 years of
clinical investigation and documented the clinical and
radiographic findings on 20 patients with MED (Fair-
bank 1909, 1925, 1927, 1935, 1946). Although Fair-
bank concluded that MED, “as a rule, is not inherited
or familial” (Fairbank 1947, p. 16), later reports clearly
established that MED could be inherited as an autoso-
mal dominant disorder (Waugh 1952; Maudsley 1955;
Shephard 1956). In 1958, Barrie et al. reported a family
with 11 affected individuals in four generations and sug-
gested that at least two genes are responsible for
MED—one for the relatively mild type seen in their fam-
ily and another for the more severe type seen in other
families.
Successive genetic-linkage and positional candi-
date–cloning studies have shown that mutations in at
least three genes can result in phenotypes within the
MED disease spectrum. Mutations in the gene encoding
cartilage oligomeric-matrix protein (COMP), a penta-
meric glycoprotein localized to the territorial matrix sur-
rounding chondrocytes, can result in Fairbank, Ribbing,
and unclassified types of MED (EDM 1; MIM 132400)
(Briggs et al. 1995, 1998; Ballo et al. 1997; Susic et al.
1997; Loughlin et al. 1998). Furthermore, it was also
determined that mutations in the gene encoding the a2
chain of type IX collagen (COL9A2) can result in the
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Figure 1 Pedigrees of two families with MED and COL9A2
mutations. a, Family K. b, Family G. In both families, an arrow in-
dicates the proband.
Fairbank type of MED (EDM 2; MIM 600204) (Briggs
et al. 1994; Muragaki et al. 1996; van Mourik et al.
1998a). Type IX collagen is a member of the FACIT
(fibril-associated collagen with interrupted triple-helix)
group of collagens and is a minor component of the
cartilage extracellular matrix (Olsen 1997). It is a het-
erotrimer, a1(IX)a2(IX)a3(IX), of polypeptides derived
from three distinct genes (COL9A1, COL9A2, and
COL9A3), and this has led us to the hypothesis that
mutations in the COL9A1 and COL9A3 genes may also
result in MED phenotypes. Preliminary evidence from
linkage analysis has confirmed that there is at least a
third MED disease locus (EDM 3; MIM 600969), but
it has not been determined whether the COL9A1 and
COL9A3 genes are involved (Deere et al. 1995; M. D.
Briggs and G. R. Mortier, unpublished data).
Because of the recent discovery that a mutation in the
intron 3 splice-donor site of COL9A2 produces the Fair-
bank type of MED (Muragaki et al. 1996), we have
screened affected individuals from 28 unrelated families
with various types of MED, for mutations in the exon
9/intron 9 splice-donor site of COL9A1 and in the exon
3/intron 3 splice-donor sites of COL9A2 and COL9A3.
These three exons encode equivalent segments of the
a1(IX), a2(IX), and a3(IX) chains, respectively, and con-
stitute part of the COL3 domain of type IX collagen. In
the present study, we report the identification of novel
mutations in the exon 3/intron 3 splice-donor site of
COL9A2 in two families with distinctive oligo-epiphys-
eal forms of MED. The position of the mutation in the
splice-donor site determines the stability of the mRNA
produced from the mutant COL9A2 allele, which may
be a contributing factor in both the pathology and the
clinical variability of MED. The findings presented in
this report confirm that MED can result from mutations
in theCOL9A2 gene and support the evidence that MED
shows considerable genetic heterogeneity.
Subjects and Methods
Clinical Summary
DNA was prepared from blood collected from both
affected and unaffected individuals in 28 families with
various types of MED. Informed consent was obtained
prior to the collection of blood samples. Clinical genet-
icists and/or radiologists with extensive experience in the
diagnosis of skeletal dysplasias have examined the clin-
ical history and appropriate x-rays of the two families
in which we identified a COL9A2 mutation.
Family K.—The proband (JK) is a 17-year-old male
of normal height (figs. 1a and 2a) who was diagnosed
in childhood with pain in the joints (mostly the knees)
and genu varum. Radiographs show major epiphyseal
changes in the knees (fig. 2b) and hands (not shown),
and almost no changes in the hips (fig. 2c). The spine
(not shown) also appears normal.
Family G.—Affected members of family G (fig. 1b)
demonstrate evidence of widespread epiphyseal dyspla-
sia affecting, particularly, the large joints of the lower
limbs (fig. 2d and e). They are slightly short in stature
(adult height is 158 cm), and all three affected individ-
uals developed genu valgum, which required surgical
correction. The proband, individual III-1 (MG), started
walking late and with a stiff gait that became more no-
ticeable during ages 5–7 years. Her legs became increas-
ingly bowed, and at age 17 years she underwent tibial
osteotomy. She has developed increasing problems with
pain in her hands, lumbar spine, and ankles. Individuals
IV-1 and IV-2 walked at age 2 years with a stiff gait.
Epiphyseal dysplasia was recognized in them in early
childhood, and they underwent tibial osteotomy for
genu valgum at ages 14 and 13, respectively. They con-
tinue to have mild joint symptoms, including intermit-
tent lumbar back pain and knee pain with swelling.
Mutational Analysis in Genomic DNA
Genomic DNA was amplified by PCR and was
screened for mutations with a combination of SSCP and
heteroduplex analysis, as described elsewhere (Briggs et
al. 1995, 1998). In brief, PCR amplifications were per-
formed in 100-ml reactions containing 1.5 mM MgCl2,
10 mM Tris-HCl pH 8.3, 50 mM KCl, 200 mM of each
dNTP, 10 pmol of each primer, 50–100 ng of genomic
DNA, and 1 U of Taq DNA polymerase. PCR cycling
consisted of 40 cycles of 94C for 1 min, 55–63C for
1 min, and 72C for 1 min. For SSCP and heteroduplex
analysis, PCR products were resolved with 6% PAGE;
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Figure 2 Radiographic findings in individual JK and affected individuals from family G. a, Individual JK at age 15 years. b, Individual
JK at age 9 years 9 mo. Note flattened and irregular epiphyses. c, Individual JK at age 11 years 5 mo. d, Individual IV-2 (family G) at age 14
years 6 mo. Note flattened irregular epiphyses and metal plates from the tibial osteotomy that was performed at age 13 years. e, Individual
IV-1 (family G) at age 10 years.
gels were precooled and were run at 4C for 4–5 h at
300 V, and the DNA was visualized by silver staining.
To screen for mutations in the exon 3/intron 3 splice-
donor site of COL9A2, DNA of the patient was am-
plified by PCR using forward (5′-caatgggccccctgaaaagct-
3′) and reverse (5′-caatcccgggcttcccgtctg-3′) primers,
located in exon 3 and intron 3, respectively (Muragaki
et al. 1996). To analyze the exon 3/intron 3 splice-donor
site of COL9A3, control genomic DNA was initially
amplified by PCR, with the use of forward and reverse
primers located in exons 3 and 4, respectively (H36F,
5′-cattgacggagaagctggtc-3′; and H44R, 5′ctctcctggtttccc-
cggct-3′ [Brewton et al. 1995]). DNA sequence generated
from this genomic fragment was then used to design a
reverse primer that was specific to intron 3 of COL9A3
(9A3in3R, 5′-gcaggatgagacaggatatca-3′). PCR with
primers H36F and 9A3in3R amplified the exon3/intron3
splice-donor site, generating the expected DNA fragment
of 140 bp. To amplify by PCR the equivalent region in
COL9A1, we predicted the genomic structure of the
COL3 domain of COL9A1, using the previously deter-
mined location of exons 1–8 (Muragaki et al. 1990) and
15–17 (McCormick et al. 1987) and the known structure
of the mouse col9a2 gene. Primers 9A1ex9F (5′-ggtga-
ccgaggtcctaagg-3′) and 9A1ex10R (5′-agctcctggctttcccg-
gtt-3′), which were predicted to lie in exons 9 and 10,
respectively, amplified a genomic fragment of 199 bp.
The location of these primers was later confirmed by the
publication of the COL9A1 genomic structure (Pihla-
jamaa et al. 1998).
Analysis of COL9A2 cDNA
RNA isolation was performed by means of TRIzol
(Gibco BRL) and cDNA, synthesized with Superscript
(Gibco BRL) according to the manufacturer’s protocol.
COL9A2 cDNA was amplified by PCR with primers
9A2ex2F (5′-agaggtccaccgggagagcgg-3′) and 9A2ex5R
(5′-cccccttggctccagttaaac-3′), located in exons 2 and 5,
respectively.
DNA sequencing
Sequencing reactions were performed with ABI
PRISM dye terminator cycle sequencing reagents (Per-
kin-Elmer) and were analyzed on an ABI 377 machine.
When an SSCP was identified, the amplified DNA was
either sequenced directly or cloned (TA Cloning Kit; In-
vitrogen), and individual alleles were sequenced. Re-
striction-endonuclease digestions were performed ac-
cording to the manufacturer’s protocol.
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Figure 3 COL9A2 splice-site mutation in family K. a, Nucle-
otide sequence of exon 3 (upper case) /intron 3 (lower case) boundary.
Shown at the top is the wild-type sequence; shown below is the se-
quence from the mutant allele. Indicated by an arrow is the GrA
transition at the last nucleotide of exon 3. b, PAGE analysis of
COL9A2 exon3/intron3 genomic DNA fragment containing the mu-
tation. The mutation disrupts a HphI restriction-endonuclease site (in-
dicated by an asterisk [*]). JK and his affected mother, UK, who are
heterozygous for the mutation, show both digested and undigested
product, whereas a control sample (lane C) shows only the digested
product.
Figure 4 COL9A2 splice-site mutation in family G. a, Nucle-
otide sequence of exon 3 (upper case) /intron 3 (lower case) boundary.
Shown at the top is the wild-type sequence; shown below is the se-
quence from the mutant allele. Indicated by an arrow is the GrC
transversion at position 5 of intron 3. b, PAGE analysis of COL9A2
exon3/intron3 genomic fragment containing the mutation. The mu-
tation creates a MaeIII restriction-endonuclease site (indicated by an
asterisk [*]). Affected individuals of family G, who are heterozygous
for the mutation, show both undigested and digested product; a control
sample (lane C) shows only the undigested product.
Results
Mutational Analysis in COL9A2
SSCP analysis of PCR-amplified genomic DNA con-
taining the exon3/intron3 splice-donor site of COL9A2
identified different aberrantly migrating bands in two
unrelated individuals with MED (not shown). Direct se-
quence analysis identified novel point mutations in the
exon3/intron 3 splice-donor site, which were confirmed
by cloning and sequencing of individual alleles.
Patient JK (individual II-1 in family K) was hetero-
zygous for a GrA transition at the last nucleotide of
exon 3 (fig. 3a). This mutation disrupted a HphI re-
striction-endonuclease site, and analysis of DNA from
his affected mother confirmed that she was also hetero-
zygous for this change (fig. 3b). Analysis of DNA from
an affected member of each of the remaining 26 families
with MED and from 20 unrelated control samples dem-
onstrated the absence of this change, confirming that it
was not a common polymorphism (data not shown).
Patient MG (individual III-1 in family G) was hetero-
zygous for a GrC transversion at position 5 of intron
3 (fig. 4a). This mutation created a MaeIII restriction-
endonuclease site, and analysis of DNA from her af-
fected sons (IV-1 and IV-2) confirmed that they were
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Figure 5 6% PAGE analysis of PCR-amplified COL9A2 cDNA
from a control sample (lane C) and from patients MG and JK. The
control shows the expected DNA fragment of 196 bp, whereas both
patient samples show both normal and shortened DNA fragments.
The white arrow indicates putative heteroduplex molecules, formed
between normal and deleted DNA fragments.
also heterozygous for the change, whereas analysis of
DNA from her unaffected husband confirmed that he
did not have the mutation (fig. 4b). Analysis of DNA
from an affected member of each of the remaining 26
families with MED and from 20 unrelated control sam-
ples demonstrated the absence of this change, confirming
that it was not a common polymorphism (data not
shown).
Analysis of mRNA Splicing
To study the effect of these mutations on the splicing
of mRNA from the mutant allele, further blood samples
were obtained from affected members of each family,
for the establishment of Epstein-Barr virus (EBV)–trans-
formed lymphoblastoid (LB) cell lines. COL9A2 cDNA
from exons 2–5 was amplified by PCR, and 6% PAGE
analysis showed the presence of both a normal-sized
DNA product and a shortened DNA product, suggestive
of the loss of exon 3 (fig. 5). Individual clones from
patients MG and JK were sequenced, which confirmed
both the identity of the normal product and the loss of
exon 3 sequence from the shortened PCR product.
In patient MG (Individual III-1 in family G), the nor-
mal and deleted PCR products were present in approx-
imately equal amounts, which would be expected in a
patient heterozygous for a splice donor–site mutation
(fig. 5). However, in patients JK (fig. 5) and UK (not
shown), the deleted PCR product was much less abun-
dant than the normal-sized PCR product. To determine
whether the reduction in the amount of the deleted PCR
product was due to either normal splicing of the mutant
mRNA or degradation of the misspliced mutant mRNA,
PCR-amplified cDNA was digested with BpmI. The rec-
ognition site for this restriction enzyme is at the exon
3/exon 4 boundary and would be predicted to cleave
DNA, containing both exon 3 and the GrA transition
at the last nucleotide (fig. 6a). Restriction-enzyme di-
gestion failed to produce a DNA fragment of the ex-
pected size (∼110 bp) or to reduce the amount of normal-
sized DNA product (fig. 6b), which suggested that the
normal-sized DNA product consisted of PCR-amplified
cDNA derived entirely from the normal allele.
Mutation Screening in the COL9A1 and COL9A3
Genes
Because of the apparent grouping of EDM 2 muta-
tions in the intron 3 splice-donor site of COL9A2, we
decided to screen for mutations in the splice-donor sites
of the equivalent exons of COL9A1 and COL9A3.
SSCP/heteroduplex analysis and HphI restriction-endo-
nuclease digestion of DNA from the exon 3/intron 3
splice-donor site of COL9A3 failed to identify a
mutation in any of the affected individuals whom we
screened in the remaining 26 families with MED. The
HphI recognition sequence (GGTGA) covers 5 bp of the
7-bp intron 3 splice-donor–consensus sequence and,
consequently, was a suitable restriction endonuclease for
analysis of this site. SSCP/heteroduplex analysis of the
exon 9/intron 9 splice-donor site of COL9A1 identified
the same aberrantly migrating bands in two unrelated
individuals. DNA sequence analysis of the cloned PCR
product identified a neutral polymorphism (T/C) at po-
sition 37 of intron 9 (data not shown), and both
individuals were heterozygous for this polymorphic
change.
Discussion
In this study we screened for mutations in specific
regions of COL9A1, COL9A2, and COL9A3 and iden-
tified two different point mutations in a splice-donor site
of COL9A2 that result in distinctive oligo-epiphyseal
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Figure 6 BpmI restriction-enzyme digestion of COL9A2 cDNA.
a, Possible combinations of COL9A2 mRNA transcripts. At the top
is the normal transcript with exons 2–5 (partial) and G as the last
nucleotide of exon 3 (boxed). In the middle is a normal-sized transcript
(exons 2–5) but with A as the last nucleotide of exon 3 (boxed). Also
enclosed in a box is the recognition sequence of BpmI. At the bottom
is the incorrectly spliced transcript showing the loss of exon 3. b, 6%
PAGE analysis of COL9A2 cDNA amplified by PCR from a control
sample (lane C) and patient JK, before () and after () digestion
with BpmI.
forms of MED (MED type II). The mutations (Ex3 [1]
GrA and IVS3DS [5] GrC) result in the skipping of
exon 3 during pre-mRNA splicing and are predicted to
lead to an in-frame deletion of 12 amino acid residues
from the COL3 domain of the pro-a2(IX) chain. These
data are in agreement with the only other COL9A2 mu-
tation reported to date (IVS3DS [2] TrC), which also
resulted in the skipping of exon 3 during pre-mRNA
processing (Muragaki et al. 1996). Furthermore, mu-
tations at positions 1 and 5 of the splice-donor sites
of other procollagen genes have been described else-
where (Human Gene Mutation Database) and have re-
sulted in exon skipping and the synthesis of shortened
pro-a chains. Mutations at the terminal nucleotide (1)
of exon 6 in the COL1A1 and COL1A2 genes have
been identified in several cases of Ehlers-Danlos syn-
drome type VII (reviewed in Byers et al. 1997), and a
similar GrA transition at the terminal nucleotide of
exon 34 of COL3A1 resulted in Ehlers-Danlos syn-
drome type IV (Kuivaniemi et al. 1995). In addition,
mutations at the 5 position of splice-donor sites in the
COL1A1, COL1A2, COL2A1, and COL3A1 genes
have been shown to result in osteogenesis imperfecta,
spondyloepiphyseal dysplasia, and Ehlers-Danlos syn-
drome type IV, respectively (Bonadio et al. 1990; Gan-
guly et al. 1991; Lee et al. 1991; Bateman et al. 1994;
Tiller et al. 1995; Nicholls et al. 1996). Interestingly, our
data suggest that, in addition to skipping exon 3 during
mRNA splicing, the Ex3 (1) GrA mutation also results
in the degradation of mRNA transcribed from the mu-
tant allele. Our studies do not argue whether this deg-
radation occurs during mRNA processing (because of
the formation of unstable splicing intermediates) or after
the completion of mRNA processing prior to or during
protein translation. Degradation of mRNA from the mu-
tant allele has been suggested as a possible disease mech-
anism in MED type II (van Mourik et al. 1998b), and,
indeed, our data do support this hypothesis in affected
members of family K. However, it is clear that this is
not a suitable explanation for MED in either family G
or the family reported by Muragaki et al. (1996). It
seems likely that a number of mechanisms may contrib-
ute to the disease pathophysiology of MED type II, and
this may ultimately be reflected in clinical variability
even within this subgroup of MED.
The mutations presented in the present study confirm
that abnormalities in a2(IX) can result in MED. Analysis
of equivalent splice-donor sites in the COL9A1 and
COL9A3 genes failed to identify mutations in affected
individuals from the remaining 26 families with MED.
Such findings would suggest that mutations in these
regions of COL9A1 and COL9A3 are not a common
cause of MED and that the contribution of these two
genes to the molecular pathology of MED remains to
be determined. It is likely that the identification of the
causative mutation in most families with MED will re-
quire extensive screening of exons from the COL9A1,
COL9A2, and COL9A3 genes, particularly when car-
tilage mRNA is not available and linkage analysis does
not implicate a specific candidate gene.
Affected members of families K and G have a dis-
tinctive oligo-epiphyseal form of MED, which is similar
to the phenotype of affected individuals in the two fam-
ilies with MED type II that have been reported elsewhere
(Barrie et al. 1958; Briggs et al. 1994; Muragaki et al.
1996; van Mourik et al. 1998a). In essence, affected
individuals in all four families are characterized by nor-
mal or mild short stature and pain and/or stiffness of
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the knees and hands. To some extent there is pain and/
or stiffness of the ankles but not of the hips. In addition,
varus or valgus deformities that develop at an early age
in affected family members sometimes require surgical
correction. These features are in direct contrast to the
clinical and radiographic presentation of individuals
with MED type I phenotypes resulting from mutations
in the COMP gene (Oehlman et al. 1994; Briggs et al.
1995, 1998; Deere et al. 1995; Ballo et al. 1997; Susic
et al. 1997; Loughlin et al. 1998). In the patients de-
scribed in these reports, the major clinical symptom is
severe hip dysplasia leading to premature osteoarthritis
and joint replacement. Although individuals with MED
type I suffer from knee pain and stiffness, and although
radiographs show flattened and irregular distal femoral
epiphyses, there appear to be none of the varus or valgus
deformities that are associated with MED type II.
The classification of MED into the Fairbank or Rib-
bing types owes much to the individual interpretation
of clinical and radiographic findings by clinical geneti-
cists and/or radiologists. This may help to explain the
variability that is seen in the diagnosis of MED phe-
notypes, and perhaps the identification of a genetic or
molecular basis of disease may help in the future to
confirm a particular diagnosis. In 1958, when Barrie et
al. predicted that mutations in at least two genes were
responsible for the phenotypic variability of MED, they
suggested that additional series of x-rays would need to
be studied to determine the extent of genetic heteroge-
neity in MED. The advent of molecular genetics has
validated their original hypothesis, and we now suggest
that abnormalities in COMP primarily produce severe
forms of MED (MED type I), whereas certain mutations
in theCOL9A2 gene produce milder forms of the disease
(MED type II). It is interesting to note that the large
family with relatively mild MED, originally reported by
Barrie et al. (1958), was the first family with MED to
be linked to COL9A2 (Briggs et al. 1994).
The findings presented in the present study provide
some rationale for the phenotypic variability seen in
MED; however, the identification of additional muta-
tions in both the COMP and type IX collagen genes will
help to elucidate further the genetic and molecular basis
of this heterogeneous disorder.
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